iiinova — where your digital self keeps evolving

A phase III randomised study of first-line NUC-1031/ cisplatin vs GemCis in advanced biliary tract cancer @JHepatology doi.org/10.1016/j.jh... 👉mOS 9.2 vs 12.6 mo 👉Early toxicity & liver injury in exp. arm 😨Not only 🚫, but even detrimental @myESMO @EASLedu @ILCAnews

🔥off the press Recent advances in systemic therapy for advanced biliary tractcancer: A systematic review & meta-analysis usingreconstructed RCT survival data @JHEP_Reports 👇now online available doi.org/10.1016/j.jh... 👉very modest progress 🧐we need biomarker & better 💊 @myESMO @EASLedu

040

Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D @CCR_AACR doi.org/10.1158/1078... 👉not all MSI tumors respond to ICI 👉NGS & RNA seq can help to identify responders @myESMO

051

Neoadjuvant mFOLFOX With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer @Annals_Oncology doi.org/10.1200/JCO-... 🔎10-yr Follow-Up of FOWARC trial 🧐neoadjuvant mFOLFOX6 is a therapeutic option in LARC

🔥off the press New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe @LancetRH_Europe doi.org/10.1016/j.la... 👉there are striking disparities in access to innovative💊& molecular testing 🧐we urgently need a more harmonised path forward

Tremelimumab & durvalumab as neoadjuvant or non-operative management strategy for MSI GC/GEJ cancer @Annals_Oncology doi.org/10.1016/j.an... 🔎 INFINITY study by GONO 👉17 pts > 13 cCR > non-operative management > only 1 recurrence 🧐W&W in GC/GEC ... exciting @myESMO

Pembrolizumab versus chemotherapy in MSI colorectal cancer @Annals_Oncology doi.org/10.1016/j.an... 🔎5-yr follow wo KEYNOTE-177 👉mPFS 16.5 vs 8.2 mo 👉mOS 77.5 vs 36.7 mo (37% cross over) 👉5-year OS rate: 54.8s% v 44.2% 🧐we need biomarker .. Nivo/Ipi vs pembro @myESMO

Clinicogenomic landscape of #PDAC identifies KRAS mutant dosage as prognostic of overall survival @NatureMedicine doi.org/10.1038/s415... 👉Very comprehensive analysis on the impact of KRAS 👉Key for understanding de novo and acquired resistance to RAS 💊 @myESMO

032

🔥off the press: Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up @Annals_Oncology doi.org/10.1016/j.an... 👉get the lastest update on HCC management 👉Multiple options > MDT is key @myESMO @EASLedu @ILCAnews #livertwitter

084

Advances in liquid biopsy: From exploration to practical application @Cancer_Cell doi.org/10.1016/j.cc... 👏Excellent review on liquid biopsy 👉LP will be key for disease monitoring and to understand resistence mechanisms @myESMO

021

Liver metastases do not predict resistance to the addition of atezolizumab to FOLFOXIRI + bevacizumab in proficient MMR mCRC @ESMO_Open doi.org/10.1016/j.es... 🔎 Post-hoc AtezoTRIBE study 👉LM prognostic, not predictive 🧐Do we need to rethink LM & ICI efficacy in mCRC? @myESMO

021

Long-term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy @JNCI_Now doi.org/10.1093/jnci... 🔎🇺🇸RWD, >200pts 👉HAI with CTx can offer long-term durable disease control: mOS >20mo @myESMO @EASLedu @ILCAnews #livertwitter

021

🔥hot off the press @ESMO_Open doi.org/10.1016/j.es... ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma 👉get the latest update on management @myESMO

Arndt Vogel @arndtvogel.bsky.social · 07/02/2025

Atezolizumab Plus CTx With or Without Bevacizumab in BTC 🔎 Clinical & Biomarker Data From Phs II IMbrave151 Trial @JCO_ASCO 👉ORR 26 vs 26% 👉mPFS 8.3 vs 7.9 mo 👉mOS 14.9 vs 14.6 mo 👉High VEGFA may be a predictive biomarker 🧐❌trail, not sure whether to proceed...

031

Arndt Vogel @arndtvogel.bsky.social · 07/02/2025

Trial of Gemcitabine, Cisplatin & Nab-Paclitaxel vs Gemcitabine/ Cisplatin in BTC @JCO_ASCO doi.org/10.1200/JCO-... 🔎SWOG S1815 phs III 👉ORR 31 vs 21 % 👉mPFS 7.5 vs 6.3 mo 👉mOS 14 vs 13.6 mo 🧐🚫 trial, maybe an option subgroups such locally advanced or gallbladder

Arndt Vogel @arndtvogel.bsky.social · 07/02/2025

Mismatch repair andMSI phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence & prognostic impact European Journal of Cancer doi.org/10.1016/j.ej... 🔎🗺️RWD, 23.893 pts 👉MMR-m status not associated with MSI in 48.9 % of cases 🧐need of comprehensive testing

061

Arndt Vogel @arndtvogel.bsky.social · 06/02/2025

Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in mCRC @JCO_ASCO doi.org/10.1200/JCO.... 🔎FIRE-4 (AIO-KRK-0114) Study 👉LB allows detection of RAS/ BRAF must in pt deemed RASwt on basis of tissue > behave like RAS/BRAF muts... 🧐Better to know..supports LB...…

040

Arndt Vogel @arndtvogel.bsky.social · 06/02/2025

Combined Analyses of ctDNA &Immunoscore in Stage III Colon Cancer 🔎Post Hoc of PRODIGE-GERCOR IDEA-France/ HORG-IDEA-Greece Trials @JCO_ASCO doi.org/10.1200/JCO.... 👉ctDNA in 19.7% of pts > independent prognostic 🖍️ 👉IS additional prognostic info in 80% 🧐Time for implantation in clinical practice..

Arndt Vogel @arndtvogel.bsky.social · 06/02/2025

fficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer @NEJM doi.org/10.1056/NEJM... 🔎Ph2-2, 204 pts, 12 tumor types 👉 bispecific antibody against HER2 & HER3, 👉ORR 30%, DoR 11.1 mo, mPFS 6.8 mo 👉ORR 40% in #PDAC, 20% in BTC 🧐Effective.. @myESMO @EASLedu @ILCAnews

Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced GC/GEJ cancer @lancet oncology doi.org/10.1016/ S1470-2045(24)00636-3 🔎 KYM901 phs 1 trial 👉ORR 29%, DCR 68% 👉SAE ≥3 68% 👉first CLDN18.2- specific ADC 🧐Phs 3 ongoing...

Thermal ablation versus surgical resection of small-size colorectal liver metastases @TheLancetOncol doi.org/10.1016/S147... 🔎COLLISION phs 3 non-inferiority trial, 300 pts 👉 stopped early 👉SAE 7 vs 20% 👉Similar OS and local control 🧐Both are effective treatment options

🔥off the press Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial 👉Just published in Nature Medicine 👉now press release: both end points positive. 🧐Practice changing.... @myesmo

030

Tiragolumab in combination with atezolizumab and bevacizumab in advanced or metastatic HCC @TheLancetOncol doi.org/10.1016/S147... 🔎 MORPHEUS-Liver phs 1b–2, 59 pts 👉ORR 43% vs 11% 👉mPFS 12.3 vs 4.2 mo 👉mOS 28.9 vs 15.1 mo 🧐anti-TIGIT looks really promising @myESMO @EASLedu @ILCAnews

Arndt Vogel @arndtvogel.bsky.social · 01/02/2025

🔥off the press Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis using reconstructed RCT survival data @JHEP_Reports doi.org/10.1016/j.jh... 👉Many trials in 1st line BTC, but not much progress 🤨we need to do better @myESMO @EASLedu

051

Arndt Vogel @arndtvogel.bsky.social · 19/01/2025

Utility of methylated DNA markers for the diagnosis of malignant biliary strictures doi.org/10.1097/HEP.... @HEP_Journal 👉identification of malignant biliary strictures is challenging 👉Bile can be valuable for NGS & methylated DNA markers @myESMO @EASLedu @ILCAnews #livertwitter @curecc

072

Arndt Vogel @arndtvogel.bsky.social · 13/01/2025

The impact of neoadjuvant therapy in patients with left-sided resectable #PDAC @Annals_Oncology doi.org/10.1016/j.an... 🔎international multicenter study2,282 pts 👉Neoadj. CTx improves OS for left-sided PDAC 👉higher benefit in pts w/ large tumors & high CA19-9 🧐We need prospective studies @myESMO

Arndt Vogel @arndtvogel.bsky.social · 10/12/2024

KRAS Variants Associated With Survival Outcomes & Genomic Alterations in Biliary Tract Cancers @JCOPO_ASCO doi.org/10.1200/PO.2... 👉 15% of BTC w/ KRAS mut 👉 KRAS G12D: IHC 38%; EHC 37% 👉 KRASG12 > worse outcome only in IHC 🧐We need KRASvariant specific strategies @myESMO @EASLedu

052

Arndt Vogel @arndtvogel.bsky.social · 05/12/2024

📣Updated recommendations for third & further lines treatment of advanced CRC @Annals_Oncology doi.org/10.1016/j.an... 🔎 ESMO mCRC Living Guideline 👉Fruquintinib recommended 👉Cetuximab–adagrasib recommended in mKRAS G12C 👉Panitumumab–sotorasib not yet approved @myESMO

062

Arndt Vogel @arndtvogel.bsky.social · 04/12/2024

📣🔥FDA grants accelerated approval to zenocutuzumab for non-small cell lung cancer & pancreatic adenocarcinoma 👉first FDA approval for NRG1 gene fusion 👉Rare, but can be found in multiple cancer types incl. CCA 👉options for🎯💊 @myESMO @ILCAnews @EASLedu

Arndt Vogel @arndtvogel.bsky.social · 04/12/2024

Tremelimumab & durvalumab as neoadjuvant or definitive management of dMMR/MSI GC or GEJ adenocarcinoma @Annals_Oncology doi.org/10.1016/j.an... 🔎 INFINITY by GONO 👉pCR: 60%; MPR 80%; 24-mo PFS 85% & OS 92% 👉76% cCR > NOM 🧐excellent efficacy for chemo-free T300/D @myESMO

000

Arndt Vogel @arndtvogel.bsky.social · 04/12/2024

First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in MTAP-deleted solid tumors @Annals_Oncology doi.org/10.1016/j.an... 🔎 phs I 👉ORR 21.4% across 8 tumor types 👉favorable safety profile 👉MTAP deletion in 15% of cholangiocarcinomas 🧐evolving options 🎯💊 @myESMO @EASLedu @ILCAnews

Arndt Vogel @arndtvogel.bsky.social · 03/12/2024

Comparison of 1st chemotherapy in unresectable locally advanced or metastatic #PDAC @TheLancetOncol doi.org/10.1016/S147... 🔎systematic review & Bayesian network meta-analysis, 79 trials, 22 168 pts 👉NALIRIFOX & FOLFIRINOX may be the preferred options if feasible @myESMO

Arndt Vogel @arndtvogel.bsky.social · 03/12/2024

Preferences for speed of access versus certainty of the survival benefit of new cancer drugs @TheLancetOncol doi.org/10.1016/S147... 🔎discrete choice experiment ❓How long are pts willing to wait for a cancer drug? 🧐trade of btw certainty & wait time 🤔Interesting food for thoughts

Arndt Vogel @arndtvogel.bsky.social · 03/12/2024

Pembrolizumab versus chemotherapy in MSI or dMMR mCRC @Annals_Oncology doi.org/10.1016/j.an... 🔎5-year follow-up from KEYNOTE-177 👉mPFS 16.5 vs 8.2 mo 👉5-yr OS rate 55% vs 44% 💪Excellent outcome in responders 🧐30% non-responder concerning > Nivo/Ipi?

Arndt Vogel @arndtvogel.bsky.social · 28/11/2024

Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types @JCOPO_ASCO doi.org/10.1200/PO-2... ? How do identify dMMR pts 👉33.8% pts with MMR mutations have MMR loss 👉only 34% of pts with MMR loss had MMR mutations 👉we need both NGS & IHC testing!

Arndt Vogel @arndtvogel.bsky.social · 28/11/2024

Outcome & management of pts with HCC who achieved complete response to ICI-based systemic therapy @HEP_Journal doi.org/10.1097/HEP.... 🔎🌎RWD, 👉1- & 3-year RFS: 78% & 55% 👉1- & 3-year OS: 98% & 86% 😅Just great to report RFS in advanced HCC w/ ICI❗️ @myESMO @EASLedu @ILCAnews #liverwitter

142

Arndt Vogel @arndtvogel.bsky.social · 28/11/2024

Nivolumab plus Ipilimumab in Microsatellite-Instability–High mCRC @NEJM doi.org/10.1056/NEJM... 🔎CM 8HW phs-3, 303 pts 👉24-mo PFS: 72% vs 14% 👉AEs Gr 3/ 4: 23% vs 48% 💪Excellent outcome w/ ICI,incl pts with liver mets, mBraf... @myESMO

030

Arndt Vogel @arndtvogel.bsky.social · 26/11/2024

🔥 FDA grants accelerated approval to zanidatamab- for previously treated unresectable or metastatic HER2-positive biliary tract cancer 👉Excellent news, another approved option for🎯💊 in BTC 👉NGS is mandatory in advanced BTC, consider Her2 IHC to identify patients @myESMO @EASLedu @ILCAnews @curecc

040

Arndt Vogel @arndtvogel.bsky.social · 26/11/2024

Liver Transplantation for Cholangiocarcinoma After Chemotherapy & SIRT: An Intention-To-Treat Study @Transpl_Int doi.org/10.3389/ti.2... 👉excellent outcome w/ LTX after sequential downstaging 🧐Intersting food for thoughts > need to identify the right pts @myESMO @EASLedu @ILCAnews #livertwitter

153

Arndt Vogel @arndtvogel.bsky.social · 25/11/2024

A simple prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: @ESMO_Open doi.org/10.1016/j.es... 🔎🇫🇷prospective FFCD-AC cohort 👉easy to use score based on lymph node invasion, tumor grade & nonintestinal subtypes @myESMO

Arndt Vogel @arndtvogel.bsky.social · 25/11/2024

Intermittent or Continuous Panitumumab + FOLFIRI for RAS and BRAF WT CRC @JCO_ASCO doi.org/10.1200/JCO.... 🔎IMPROVE phs-3 👉ORR 68.1% vs 61.2%, 👉mPFS 11.2 vs 17.5 mo, left-sided w/ delayed resistance 👉mOS 36.3 vs 35.1 mo 🧐Deescalation is feasible, less tox @myESMO